Dose, schedule, safety, and efficacy of guadecitabine in relapsed or refractory acute myeloid leukemia

BACKGROUND: Outcomes for patients with relapsed or refractory acute myeloid leukemia (AML) are poor. Guadecitabine, a next‐generation hypomethylating agent, could be useful in treating such patients. METHODS: In this multicenter, open‐label, phase 2 dose‐expansion study, AML patients from 10 North A...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Cancer
Autori principali: Roboz, Gail J., Kantarjian, Hagop M., Yee, Karen W. L., Kropf, Patricia L., O'Connell, Casey L., Griffiths, Elizabeth A., Stock, Wendy, Daver, Naval G., Jabbour, Elias, Ritchie, Ellen K., Walsh, Katherine J., Rizzieri, David, Lunin, Scott D., Curio, Tania, Chung, Woonbok, Hao, Yong, Lowder, James N., Azab, Mohammad, Issa, Jean‐Pierre J.
Natura: Artigo
Lingua:Inglês
Pubblicazione: John Wiley and Sons Inc. 2017
Soggetti:
Original Articles
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC5814873/
https://ncbi.nlm.nih.gov/pubmed/29211308
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.31138
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi